Spectrum Pharmaceuticals, Inc. (SPPI): Price and Financial Metrics

Spectrum Pharmaceuticals, Inc. (SPPI): $0.73

-0.05 (-6.14%)

POWR Rating

Component Grades













Add SPPI to Watchlist
Sign Up

Industry: Biotech



in industry

SPPI Stock Price Chart Interactive Chart >

Price chart for SPPI

SPPI Price/Volume Stats

Current price $0.73 52-week high $4.54
Prev. close $0.78 52-week low $0.60
Day low $0.73 Volume 2,063,000
Day high $0.81 Avg. volume 3,882,906
50-day MA $0.99 Dividend yield N/A
200-day MA $1.50 Market Cap 131.48M

Spectrum Pharmaceuticals, Inc. (SPPI) Company Bio

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. The company was founded in 1987 and is based in Henderson, Nevada.

SPPI Latest News Stream

Event/Time News Detail
Loading, please wait...

SPPI Latest Social Stream

Loading social stream, please wait...

View Full SPPI Social Stream

Latest SPPI News From Around the Web

Below are the latest news stories about Spectrum Pharmaceuticals Inc that investors may wish to consider to help them evaluate SPPI as an investment opportunity.

Spectrum Pharma announces resignation of CFO

The shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) are trading marginally lower in the pre-market on Wednesday after the commercial-stage biotech company announced the resignation of its Chief Financial Officer Kurt Gustafson. According to a regulatory filing, Mr. Gustafson has notified the company of his decision on Feb. 23, indicating his resignation...

Seeking Alpha | February 23, 2022

Spectrum Pharmaceuticals (SPPI) Receives a Buy from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $6.00. The company's shares closed last Friday at $0.72, close to its 52-week low of $0.60. According to TipRanks.com, Mamtani 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.7% and a 29.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Cognition Therapeutics. Currently, the analyst consensus on Spectrum Pharmaceuticals is a Strong Buy with an average price target of $6.67.

Catie Powers on TipRanks | February 11, 2022

Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib

HENDERSON, Nev., February 11, 2022--Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib

Yahoo | February 11, 2022

Down 55.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)

The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | February 1, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | January 28, 2022

Read More 'SPPI' Stories Here

SPPI Price Returns

1-mo -20.37%
3-mo -1.12%
6-mo -58.99%
1-year -78.08%
3-year -90.52%
5-year -87.30%
YTD -42.52%
2021 -62.76%
2020 -6.32%
2019 -58.40%
2018 -53.83%
2017 327.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8117 seconds.